Streamlining Pulmonology InterQual Reviews with Klivira Automation

Navigating **pulmonology InterQual** criteria for prior authorization can be a significant bottleneck in delivering timely patient care. Klivira automates the complex review process, ensuring adherence to evidence-based guidelines and accelerating approvals.

Revenue cycle directors and prior authorization coordinators in pulmonology face unique challenges, from managing high-cost biologics to ensuring appropriate home medical equipment. InterQual criteria, developed by Change Healthcare / Optum, serve as critical medical necessity benchmarks for many payers. Effectively integrating these criteria into your PA workflow is essential for minimizing denials and optimizing patient access to vital respiratory treatments.

The Role of InterQual in Pulmonology Prior Authorization

InterQual criteria provide evidence-based clinical guidelines used by payers to determine the medical necessity of various pulmonology services and treatments. For conditions ranging from severe asthma requiring biologics to chronic respiratory failure necessitating home oxygen, adherence to these criteria is paramount for securing prior authorization. Klivira integrates these guidelines into an automated workflow, ensuring that submissions meet payer requirements proactively.

Key Pulmonology Treatments Requiring InterQual Review

Asthma biologics, including omalizumab (Xolair), mepolizumab (Nucala), reslizumab (Cinqair), benralizumab (Fasenra), dupilumab (Dupixent), and tezepelumab (Tezspire).
COPD specialty drugs like ensifentrine (Ohtuvayre) and specific triple-therapy inhalers.
Idiopathic Pulmonary Fibrosis (IPF) antifibrotics, such as pirfenidone (Esbriet) and nintedanib (Ofev).
Home oxygen therapy and non-invasive ventilation (BiPAP/CPAP) for chronic respiratory conditions.
Lung transplant evaluation and associated immunosuppression regimens.

Navigating Clinical Guidelines and Documentation for Pulmonology InterQual

Successful InterQual submissions in pulmonology hinge on meticulous documentation aligned with established clinical guidelines. Payers frequently reference recommendations from bodies like the American Thoracic Society (ATS), Global Initiative for Asthma (GINA), and Global Initiative for Chronic Obstructive Lung Disease (GOLD). For asthma biologics, specific data points such as eosinophil counts, history of prior controller therapy at maximum dose, and exacerbation history are often required to meet medical necessity criteria.

Common Challenges in Pulmonology InterQual Reviews

Pulmonology prior authorizations frequently encounter denials due to specific clinical criteria not being met. Common reasons include failure to demonstrate adherence to step-therapy protocols for asthma biologics, not meeting required eosinophil-count thresholds for IL-5 targeting therapies, or insufficient documentation of conservative therapy trials for conditions like IPF. These issues highlight the need for a robust system to ensure all necessary clinical evidence is presented upfront.

Klivira's Approach to Streamlining Pulmonology InterQual Workflows

Klivira's platform is engineered to address the complexities of pulmonology prior authorizations guided by InterQual criteria. Our system incorporates GINA, GOLD, and ATS-aware step-therapy logic, automates the capture and submission of critical data like eosinophil counts, and streamlines re-authorization workflows for long-term asthma biologic treatments. By integrating directly with EMRs and payer portals, Klivira reduces manual effort and improves the accuracy of submissions.

EMR and Payer Touchpoints for Pulmonology PA Automation

Automated extraction of clinical data (e.g., PFT results, eosinophil counts, medication history) from EMRs via SMART on FHIR and other integration methods.
Submission of X12 278 transactions and ePA requests through NCPDP SCRIPT standards to payer portals.
Utilization of Da Vinci PAS implementation guides for efficient information exchange.
Integration with order entry systems to proactively identify PA requirements for high-cost biologics and durable medical equipment.
Real-time status updates and documentation uploads to patient charts within the EMR.

Frequently asked questions

How does Klivira handle step-therapy requirements for asthma biologics in pulmonology?

Klivira's platform incorporates GINA, GOLD, and ATS-aware logic to guide users through payer-specific step-therapy requirements for asthma biologics. It helps ensure that documentation of prior controller therapy at maximum doses and exacerbation history is accurately captured and submitted, reducing denials related to unmet step-therapy criteria.

What specific documentation is critical for pulmonology InterQual submissions?

Critical documentation for pulmonology InterQual submissions often includes pulmonary function test results, eosinophil counts (for certain biologics), detailed medication history (especially prior controller therapies), exacerbation history, and evidence of adherence to clinical guidelines from bodies like ATS, GINA, and GOLD. Klivira streamlines the collection and presentation of this data.

Can Klivira integrate with our EMR to pull pulmonology PA data?

Yes, Klivira is designed for deep integration with various EMR systems. We leverage standards such as SMART on FHIR to extract relevant clinical data for pulmonology prior authorizations, including patient demographics, diagnoses, medication lists, and lab results, minimizing manual data entry for your team.

How does Klivira help with re-authorizations for long-term pulmonology treatments?

For long-term pulmonology treatments like asthma biologics or home oxygen, re-authorizations are common. Klivira automates the re-authorization workflow by tracking approval expiration dates, prompting for updated clinical documentation, and facilitating timely resubmissions to payers, ensuring continuity of care and preventing lapses in coverage.

What are the most common reasons for InterQual denials in pulmonology?

Common InterQual denial reasons in pulmonology include failure to meet step-therapy requirements for asthma biologics, not reaching specific eosinophil-count thresholds for IL-5 targeting therapies, or insufficient documentation of conservative therapy trials for conditions like IPF. Klivira helps mitigate these by ensuring comprehensive and compliant submissions.